Research & Technology Organization
Universidad de Alcalá-OTRI posted this:Development and method of construction of a new electrochemical sensor of Magnesium (Mg2 +), without the need to add organic salts, additives or organic solvents to the sampleThe research group in Bioelectrochemistry and Biosensors of the University of Alcalá in collaboration with the Textile Industry Research Association (AITEX) has developed an electrochemical sensor of magnesium (Mg2 +) and a construction method based on the formation of a polymeric three-dimensional network that allows the entrapment / immobilization of a selective indicator for Mg2 +, eriochrome black T, by the use of a crosslinking agent and a polymer. The combination of these three reagents allows the construction of the sensor on any conductive surface, avoiding the electro polymerization of the indicator. The resulting sensor allows to measure MG2 + in any type of samples, without the need to add organic salts, additives or organic solvents. The quantification of Mg2 + is done directly by incubating the sensor in the sample containing the analyte, resulting in a modification of the amperometric signal proportional to its concentration. This method has many applications especially in health and biomedical sector since Mg2 + participates in such important activities as neuronal, neuromuscular transmission, or regulation of blood pressure and plays a key role in various pathologies such as vascular and migraines headache. The group is looking for companies in the agro-food, bio-sanitary and environmental sectors, with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses.
Germans Trias i Pujol Health Sciences Research Institute (IGTP) posted this:Apotransferrin to treat strokeOur group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes). Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.
Germans Trias i Pujol Health Sciences Research Institute (IGTP) posted this:Diagnostic biomarkers for dementia with Lewy BodiesThe present data provide a solid basis for the development of genetic biomarkers for the early identification of patients suffering from dementia with Lewy bodies and to classify them into specific molecular subtypes. One of the biomarkers correlates with the development of Lewy pathology in the brain and may be useful to monitor the success of possible alpha-synuclein antiaggregatory therapies.
University of Vigo posted this:Pyridazin-3(2H)-one Derivatives as Selective Inhibitors of Monoamine Oxidase-B Isoform (MAO-B)The pyridazine ring is a privileged fragment found in compounds with very different pharmacological properties, such as antihypertensive, antiplatelet, anti-inflammatory, antinociceptive, antidepressant, hypoglycemic, antiinfective or anticancer agents, many of them being pyridazin-3(2H)-one derivatives. The pyridazine ring is also included in polycyclic compounds acting as MAO-B inhibitors. However, simple pyridazin-3(2H)-one derivatives have not been described so far as selective MAO-B inhibitors. The present invention provides novel pyridazin-3(2H)-one derivatives substituted at C4, C5 or C6 with several dithiocarbamate moieties that selectively inhibit the MAO-B activity and whose structure is unrelated to those currently available.
Centre Technology Transfer CITTRU posted this:New drug candidates for treatment of neuropathic pain and epilepsy.Despite the large number of available antiepileptic drugs, approximately 30% of patients fail to control seizures, and among those experiencing partial seizures (simple, complex, and secondarily generalized) the percentage is even higher at around 40%. Such a form of epilepsy is called drug resistance. One reason for the wide prevalence is the problem of insufficient efficacy of the currently available antiepileptic drugs. Also neuropathic pain in many cases is unable to control with use of currently used drugs. One of the possible reasons is that there are many mechanisms for the formation of the peripheral and central neuropathic pain, which frequently are still poorly known. Neuropathic pain is a serious clinical problem which affects up to 7 ‐ 8% of the population. Compounds included in the offer meet requirements for new, innovative drugs efficient in epilepsy and neuropathic pain cases which are still unmet medical needs (particularly drug resistant epilepsy and uncontrolled neuropathic pain – frequently of unknown etiology).
Technology Transfer Office